Corteva

CTVA

Market cap $41.6B

Corteva, Inc. (CTVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Corteva, Inc. is splitting into two companies, creating uncertainty but maintaining strong equity coverage for its preferred stocks. The preferred stocks, CTA.PR.A and CTA.PR.B, will remain with the new Corteva entity, which retains 44% of current sales and global diversification. Both preferreds offer investment-grade ratings, cumulative dividends, and low call risk, making them attractive for portfolio diversification.

ITHACA, N.Y.--(BUSINESS WIRE)--Ascribe Bio Closes $12 Million Series A Financing to Advance Next-Generation Natural Crop Protection Co-Led by Acre Venture Partners and Corteva.

Investors watch Wall Street for signals about potential movement in stocks, and an upgrade from analysts is one important marker of shifting fundamentals. Analyst upgrades come in response to a variety of internal and external factors, and an upgrade does not necessarily mean that a company is likely to also have upside in its near future—nor even that it may be a strong choice for many investors at all.

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.

Here is how Corteva, Inc. (CTVA) and Local Bounti Corporation (LOCL) have performed compared to their sector so far this year.

EMERYVILLE, Calif.--(BUSINESS WIRE)--Profluent Bio, a pioneer in generative AI for protein design, announced today a strategic collaboration with Corteva, a global leader in agricultural sciences and solutions. Under the collaboration, the companies will use artificial intelligence (AI) and gene editing to deliver a new generation of more sustainable, resilient crops. The collaboration, which is enabled through Corteva's Catalyst platform, will focus on designing targeted, AI-driven gene-editin.

The Agriculture - Operations industry is navigating rising costs and trade pressures while tapping growth in health-focused products and innovation. CTVA, ADM, DOLE and AVO look promising.

Corteva Inc (NYSE:CTVA) Inc shares face headwinds as the agricultural macroeconomic setup into 2026 looks “challenging” with subdued grain prices pressuring farmer margins, Citi analysts wrote in a note to clients on Thursday.  They downgraded Corteva to ‘Neutral' from ‘Buy' with a target price of $67 per share.

Corteva, Inc. (CTVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.